Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.
December 12, 2017
California Drug Developer Tosk, Inc. Announces Two Milestones for Transformational Cancer Treatment
March 20, 2018

Tosk has been awarded a $2 million grant from National Cancer Institute to continue the company’s TK-kRAS research program.

The National Cancer Institute (NCI) has awarded Tosk a two-year, $2 million grant to continue its highly promising oncologic kRAS research program. The kRAS project is the NCI’s number one priority.

Some 40 percent of all cancer patients have the kRAS genetic trait, which renders certain cancer therapies ineffective. Besides enabling patients with the kRAS gene to benefit from treatment, the work that Tosk is doing could also be used as a direct cancer therapy for pancreatic and other cancers.

A portion of Tosk’s original kRAS program was financed by a Phase I Small Business Innovation research grant from the NCI. The just announced $2 million is a Phase II grant. Tosk is collaborating with Texas Tech University on this program through the company’s Scientific Advisory Board member Professor Jeff Thomas.